{"schema_version":"secwatch.filing_event.v1","accession":"0001759138-26-000030","form_type":"8-K","ticker":"CABA","cik":"0001759138","company_name":"Cabaletta Bio, Inc.","filed_at":"2026-06-03T11:02:06+00:00","discovered_at":"2026-06-03T11:05:00.318854+00:00","generated_at":"2026-06-03T11:05:32.977707+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cabaletta Bio reports positive rese-cel data at EULAR; registrational plans for SSc, DM/ASyS, JDM updated","bullets":["83% (5/6) DM patients achieved immunomodulator-free moderate/major TIS response at 16 weeks; all maintained through 1.5 years.","First two PC-free lupus patients: one achieved deep B cell depletion; PK/PD suggests lowest dose is threshold, enabling potential outpatient use.","SSc registrational study of ~25 patients with ILD to start 4Q26; primary endpoint FVC at 52 weeks.","DM/ASyS registrational cohort topline data expected mid-2027; JDM to be included in 2H27 BLA with potential priority review voucher.","Safety: no ICANS in myositis; 87% SSc patients no/grade1 CRS; 94% SLE preconditioning no/grade1 CRS."],"urls":{"canonical":"https://secwatch.observer/filing/0001759138-26-000030","json":"https://secwatch.observer/filing/0001759138-26-000030.json","markdown":"https://secwatch.observer/filing/0001759138-26-000030.md","text":"https://secwatch.observer/filing/0001759138-26-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759138/000175913826000030/0001759138-26-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759138/000175913826000030/caba-20260603.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T11:05:32.977707+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}